Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care.
In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guests Dr. Kevin Garey and a patient to discuss the impact of recurrent CDI on patients and their lives. This episode does not offer Continuing Medical Education (CME) credits. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.
This episode does not offer Continuing Medical Education (CME) credits.
Faculty:
Paul Feuerstadt MD, FACG, AGAF, Assistant Clinical Professor of Medicine
Division of Digestive Disease, Yale-New Haven Hospital
PACT Gastroenterology Center
Milford, CT
Sahil Khanna, MBBS, MS, MD, Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
Kevin W. Garey, PharmD, MS, FASHP
Professor and Chair of the Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, TX
Patient
Learning Objectives:
After completing all 6 episodes in this series, learners should be able to:
- Discuss differences between subspecialty guidelines and how to take a patient-centered approach to treatment.
- Determine the sensitivity and specificity of available laboratory tests and the recommended two-step testing algorithm.
- Examine emerging treatment options, including microbiome therapies and the future role of FMT.
- Discuss best practices for transitions of care including documenting patient history and providing instructions for patients and caregivers.
Disclosures
Faculty
Paul Feuerstadt, serving as faculty and planner for this educational activity, disclosed the following relevant financial relationships:
- Speaking / Teaching: Merck & Co., and Ferring / Rebiotix, Seres Therapeutics and Takeda Pharmaceuticals
- Advisory Committee / Review Panel: Ferring / Rebiotix, Seres Therapeutics, Takeda Pharmaceuticals, Summit Therapeutics
- Planning Committee
Sahil Khanna, serving as faculty and planner for this educational activity, disclosed the following relevant financial relationships:
- Grant / Research Support: Ferring / Rebiotix, Vedanta, Finch, Seres, and Pfizer
- Consulting: ProbioTech, Takeda, Niche and Immuron
Rebecca Perez, serving as faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose.
Cheri Lattimer, serving as faculty for this educational activity, disclosed the following relevant financial relationships:
- Speaking / Teaching: Ferring Pharmaceuticals
All relevant financial relationships have been mitigated.
Planning Committee
- Paul Feuerstadt, serving as co-chair for this educational activity, disclosed the relevant financial relationships shared above.
- Sahil Khanna, serving as co-chair for this educational activity, disclosed the relevant financial relationships shared above.
- Monique Dyson, serving as AGA staff for this educational activity, has no financial relationship to disclose.
- Maura Davis, serving as AGA staff for this educational activity, has no financial relationship to disclose.
- Katie Duggan, serving as AGA staff for this educational activity, has no financial relationship to disclose.
- Amanda Rock, serving as AGA staff for this educational activity, has no financial relationship to disclose.
- Faruq Pradhan, serving as AGA CME Subcommittee reviewer for this educational activity, has no financial relationship to disclose.
- Ngozi Enwerem, serving as AGA CME Subcommittee reviewer for this educational activity, has no financial relationship to disclose.
- Kenneth Hung, serving as AGA CME Subcommittee reviewer for this educational activity, has no financial relationship to disclose.
- Naemat Sandhu, serving as AGA CME Subcommittee reviewer for this educational activity, has no financial relationship to disclose.
All relevant financial relationships have been mitigated.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Aug. 28, 2025
Commercial Support:
This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.
| Title | Credit(s) | |
|---|---|---|
| 1 |
(0 votes)
|
|
| 2 |
(0 votes)
|
|
| 3 |
(0 votes)
|